Table 1. . Stereotactic body radiotherapy in hepatocellular carcinoma.
| Author | Institution | Design | Pts | CP class | Prior non-RT therapies (%) | Tumor size (range) | TVT (%) | Dose (Gy) | Fx | ORR (%) | 1-year OS | 1-year LC (%) | Grade ≥3 toxicity (%) | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bujold et al. | Princess Margaret Hospital | Phase I/II | 102 | A | 52 | 1.4–23.1 cm | 55 | 36 (24–54) | 6 | 54 | 55 | 87 | 36 | [44] |
| Mendez-Romero et al. | Erasmus MC, Netherlands | Phase I/II | 8 | A, B | NR | 0.5–7.2 cm | 25 | 25–37.5 | 3–5 | NR | 75 | 75 | 12.50 | [45] |
| Kang et al. | KIRMS | Phase II | 47 | A, B | 100 | 1.3–8 cm | 11 | 57 (42–60) | 3 | 76.6 | 69 at 2 years | 95 at 2 years | 26 | [46] |
| Cárdenes et al. | Indiana | Phase I | 17 | A, B | 23.5 | ≤6 cm (cumulative) | 18 | 36–48 | 3–4 | 81 | 75 | 100 | 18 | [47] |
| Tse et al. | Princess Margaret Hospital | Phase I | 31 | A | 61 | 9–1913 ml | 42 | 36 (24–54) | 6 | 49 | 48 | 65 | 26 | [43] |
| Ibarra et al. | Multi-institutional | Pooled Analysis | 21 | A, B | 76.2 | 9.5–1493.8 ml | NR | 30 (18–50) | 1–10 | 26.8 | 87 | 64 | 8 RILD only | [48] |
| Yamashita et al. | Multi-instiutional | Retrospective | 79 | A, B, C | 100 | 0.6–7 cm | NR | 48 (40–60) | 4 | 81 | 52.9 at 2 years | 74.1 | No RILD | [61] |
| Sanuki et al. | Tokai University, Japan | Retrospective | 185 | A, B | 60 | 0.8–5 cm | NR | 30–40 | 5 | NR | 95 | 99 | 13 | [49] |
| Jang et al. | KIRMS | Retrospective | 108 | A, B | 100 | 1–7 cm | NR | 51 (33–60) | 3 | NR | 63 at 2 years | 87 at 2 years | 10† | [50] |
| Yoon et al. | Asan Medical Center, Korea | Retrospective | 93 | A, B | 98.9 | 1–6 cm | 0 | 30–60 | 3–4 | 61.2 | 86 | 95 | 6.5 RILD only | [51] |
| Bibault et al. | Lille, France | Retrospective | 75 | A, B | 51 | 3–4.4 cm | NR | 45 (24–45) | 3 | NR | 79 | 90 | 16† | [52] |
| Honda et al. | Hiroshima, Japan | Retrospective | 30 | A, B | 100 | 1–3 cm | 0 | 48–60 | 4–8 | 96.3 | 100 | 100 | 7 | [53] |
| Yuan et al. | Tianjin Medical University, China | Retrospective | 22 | A, B, C | NR | 1.6–9.5 cm | NR | 45 (39–54) | 3–8 | 91 | 73 | 93 | 4.5 Grade ≥2 | [54] |
| Huang et al. | Taipei, Taiwan | Retrospective | 36 | A, B, C | 100 | 1.1–12.3 cm | NR | 37 (25–48) | 4–5 | 58.6 | 64 at 2 years | 98 | 3 | [55] |
| Andolino et al. | Indiana | Retrospective | 60 | A, B | 10 | 1–6.5 cm | NR | 44 (24–48) | 3–5 | 70 | 67 at 2 years | 90 at 2 years | 37 | [56] |
| Son et al. | Gyeongsang University, Korea | Retrospective | 47 | A, B, C | 78 | 3.0–81.3 ml | NR | 30–39 | 3 | NR | NR | NR | 33 Grade ≥2 | [57] |
| Kwon et al. | Catholic University, Korea | Retrospective | 42 | A, B | 81 | 3.0–81.8 ml | 0 | 30–39 | 3 | 85.8 | 93 | 72 | 2 | [58] |
| Seo et al. | KIRMS | Retrospective | 38 | A, B | 100 | <10 cm | NR | 33–57 | 3–4 | 63.1 | 69 | 79 | 3 | [59] |
| Louis et al. | Liege, Belgium | Retrospective | 25 | A, B | 36 | 1.8–10 cm | 16 | 45 | 3 | 86 | 79 | 95 | 8 | [60] |
†Toxicities may include some redundancies.
CP class: Child–Pugh class; Fx: Fractions; KIRMS: Korea institute of radiological and medical sciences; LC: Local control; NR: Not reported; ORR: Overall response rate (CR+PR); OS: Overall survival; Pts: Patients; RILD: Radiation-induced liver disease; RT: Radiotherapy; TVT: Tumor vein thrombosis.
Adapted with permission from [62] © The Oncologist (2014).